Alizé Pharma 3 Raises €67m To Build ‘Fully Fledged’ Biotech
The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.
The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.